Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemo-immunotherapy with trastuzumab + lapatinib + paclitaxel in HER2-positive early breast cancer
2012-003679-21Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, lapatinib and paclitaxel in breast cancer, sponsored by Westdeutsche Studiengruppe. Primary endpoint: Pathological complete response at surgery. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003679-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003679-21.